Perelló-Trias M Teresa, Rodríguez-Fernández Ana, Serrano-Muñoz Antonio Jose, Segura-Sampedro Juan J, Tauler Pedro, Ramis Joana M, Monjo Marta
Cell Therapy and Tissue Engineering Group (TERCIT), Research Institute on Health Sciences (IUNICS), University of the Balearic Islands (UIB), 07122 Palma, Mallorca, Spain.
Health Research Institute of the Balearic Islands (IdISBa), 07010 Palma, Mallorca, Spain.
ACS Pharmacol Transl Sci. 2025 Jan 8;8(2):499-509. doi: 10.1021/acsptsci.4c00608. eCollection 2025 Feb 14.
Peritoneal carcinomatosis (PC) is typically treated by cytoreductive surgery (CRS) and subsequent chemotherapy. Sealing hemostatic patches (HP) are often used during these surgeries to prevent complications such as uncontrolled bleeding. These HP are made of biomaterials like oxidized cellulose or collagen with a binding agent, and beyond their usual function, they could also be used as drug delivery systems (DDS) for localized intraperitoneal chemotherapy in the tissue attached. Our first aim was to characterize and compare three different commercial HP (TachoSil®, Hemopatch®, and Veriset). Hemopatch® emerged as the most suitable candidate due to its combination of properties, including slow degradation, high hydrophilicity, excellent biological fluid absorption capacity, and moderate adhesive capacity alongside hemostasis. Utilizing Hemopatch® as a scaffold, we developed a new device incorporating a hyaluronic acid hydrogel loaded with cisplatin or olaparib. This approach facilitated sustained drug release for over 6 days, maintaining the anticancer efficacy of these agents on OVCAR-3 cells. In conclusion, integrating a DDS into HP shows potential for precisely delivering chemotherapeutic agents to any residual microscopic disease in PC following CRS.
腹膜癌病（PC）通常采用细胞减灭术（CRS）及后续化疗进行治疗。在这些手术过程中，常使用封闭止血贴片（HP）来预防诸如无法控制的出血等并发症。这些HP由氧化纤维素或胶原蛋白等生物材料与粘合剂制成，除了其常规功能外，它们还可用作附着组织中局部腹腔内化疗的药物递送系统（DDS）。我们的首要目标是表征和比较三种不同的商用HP（速即纱®、Hemopatch®和Veriset）。由于其综合性能，包括降解缓慢、亲水性高、生物流体吸收能力优异、止血的同时具有适度的粘附能力，Hemopatch®成为最合适的候选产品。以Hemopatch®为支架，我们开发了一种新装置，该装置包含负载顺铂或奥拉帕尼的透明质酸水凝胶。这种方法促进了药物持续释放超过6天，维持了这些药物对OVCAR-3细胞的抗癌功效。总之，将DDS整合到HP中显示出在CRS后将化疗药物精确递送至PC中任何残留微小病灶的潜力。
